Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

NCT06442709 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Tocilizumab Asprin
OTHER: Placebo

Sponsor

Affiliated Hospital of Nantong University